Complix

Technologiepark 94
9052 Zwijnaarde
BE
Complix
Foundation date
23/06/2008
Sector
#Biotechnology - TherapeuticsSubsector
Therapeutic areas
- #Cardiovascular
- #Diseases of the blood and blood-forming organs - immune disorders
- #Infectious and parasitic diseases
- #Neoplasms / cancer / oncology
Complix is a biopharmaceutical company engaged in the discovery and development of Alphabodies™, a revolutionary class of biopharmaceuticals with exceptional properties. Alphabodies™ combine beneficial properties of small molecules with those of antibodies, and can address intracellular as well as extracellular disease targets that are undruggable by antibodies or small chemical drugs. Complix has developed a balanced pipeline of transformative protein therapeutics in oncology, autoimmunity/inflammation and viral diseases.
Upcoming events
All events-
0106 '23
KNOWLEDGE FOR GROWTH 2023
Event by: flanders.bio -
0506 '23
BIO International Convention 2023
Event by: Biotechnology Innovation Organisation -
0604 '23
Innovation for Health 2023
Event by: Hyphen Projects
Latest news
More news-
Celyad Oncology appoints Georges Rawadi as its new CEO
Tuesday March 28th 2023
Read more
-
BioLizard appoints Paul Vauterin as Chief Technology Officer
Monday March 27th 2023
Read more
-
ImmuneWatch receives Antwerp Innovation grant to accelerate vaccine development with AI
Monday March 27th 2023
Read more
Jobs
More jobs-
-
28/03/23
East Flanders
Postdoc researcher: Unravelling proteostasis machineries in jasmonate signalling in tomato
Permanent
VIB -
28/03/23
East Flanders
PhD student: Phosphoregulation in jasmonate-mediated plant stress responses
Permanent
VIB